Europe PDE Inhibitors Market Report

Europe PDE Inhibitors Market Size

The europe PDE inhibitors market size was valued at USD 1.29 billion in 2025 and is anticipated to reach USD 1.38 billion in 2026 from USD 2.29 billion by 2034, growing at a CAGR of 6.55% during the forecast period from 2026 to 2034.

The advent of selective phosphodiesterase enzyme inhibitors has had a significant impact on the medical treatment industry, helping better understand and produce better therapeutic drugs.

For instance, researchers at Johns Hopkins University are conducting trials of PDE-5 inhibitors in pediatric patients with pulmonary hypertension. This provides novel medication for infants, neonates, and children with primary and secondary pulmonary hypertension. Such ongoing research and development activities will support the market during the upcoming years. In addition, the development of PDE4 inhibitors for treating various inflammatory diseases, including asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, and psoriasis, is growing at a high rate. For example, recent clinical trials support the success of roflumilast in COPD treatment and sildenafil for erectile dysfunction (ED), popularizing the demand for PDE inhibitors.

The growing prevalence of ED can be attributed to several factors, including diabetes mellitus, substance abuse, testosterone deficiency, lifestyle changes, specific medication, prostate cancer, obesity, hypertension, and hyperlipidemia. According to the World Health Organization, around 151 million people have been affected by erectile dysfunction worldwide, and this number is estimated to reach 235 million by 2025. In addition, rapid urbanization, environmental pollution, aging, and high stress support the increase in chronic disorders, especially in the young population. Thus, the rising incidence of chronic diseases is anticipated to drive the adoption of PDE inhibitors and drive the market at a steady rate during the forecast period.

However, certain factors such as the potent drug interactions of PDE inhibitors, lack of reimbursement policies, side effects associated with PDE inhibitors, and the launch of generics might hamper the growth of the Europe PDE inhibitors market during the forecast period.

The United Kingdom PDE inhibitors market is estimated to grow rapidly during the aforementioned forecast period.

Various factors supporting this regional market growth include increased awareness of the disease and treatment modalities, the presence of major pharmaceutical companies offering branded and generic PDE inhibitors, and a rapid increase in the target audience. Erectile dysfunction is linked to an increased risk of cardiovascular disease (CVD), dementia, and premature death, affecting up to one in five men or nearly 4.35 million men in the UK. Reports also suggest a common medical condition that affects around 15 % of men each year.

The regional markets in Germany and France are expected to grow at a lucrative incremental growth rate over the forecast period. Well-established healthcare infrastructure, increased awareness of the disease, increasing awareness about various diseases, supportive R&D activities, and key players are likely to increase the market in these regions. In France, the current prevalence of chronic obstructive pulmonary disease (COPD) is estimated at over 2.6 million and is analyzed to reach approximately 2.8 million by 2025. While in France, the prevalence of COPD is recorded as 13.22%, as it is very common in Germany.

KEY MARKET PLAYERS

A few notable companies operating in the European PDE inhibitors market include

• Mist Pharmaceuticals
• AstraZeneca
• Nusirt Biopharma
• Takeda Pharmaceuticals
• Bayer AG
• Pfizer
• Otsuka
• Eli Lilly
• Verona Pharma
• Omeros
• Hanmi Science Holding
• Celgene Corporation.

MARKET SEGMENTATION

This research report on the European PDE inhibitors market has been segmented and sub-segmented into the following categories.

By Drug Type

• Selective PDE inhibitors     

  • PDE-1

  • PDE-2
  • PDE-3
  • PDE-4
  • PDE-5
  • Others (PDE-6 to PDE-11)
• Non-selective PDE inhibitors           
  • Viagra
  • Cialis
  • Levitra
  • Other Drugs

By Application

• Pulmonary Hypertension  
• Cardiovascular Diseases    
• Benign Prostate Hyperplasia           
• Respiratory Diseases          
• Neurological Diseases        
• Dermatological Disorders  
• Erectile Dysfunction            
• Other Applications 

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe